01—Abstract
Summary
Summary of the 8-K filed April 11, 2025. Cited figures are marked; the original filing is the authoritative source.
On April 11, 2025, Royalty Pharma plc filed a Form 8-K disclosing Amendment No. 1 to the Membership Interests Purchase Agreement previously announced on January 10, 2025.
Under the original agreement, Royalty Pharma Holdings Ltd. (RPH), a subsidiary of Royalty Pharma plc, will acquire all equity interests of Royalty Pharma Manager, LLC (formerly Royalty Pharma, LLC) and RP Management, LLC from the named Sellers. The Transaction is subject to shareholder approval, and the company states it will file a proxy statement on Schedule 14A seeking that approval. Amendment No. 1, entered into by RPH, Royalty Pharma plc and Pablo Legorreta as Seller Representative, makes the parent company a party to the Purchase Agreement.
At closing, each Seller will subscribe for Class B ordinary shares of Royalty Pharma plc equal in number to the non-voting Class E ordinary shares of RPH they receive as consideration. The Class B shares are issued at their nominal value of US$0.000001a each, payable in cash at closing. The filing is largely procedural.
It sets out the structure for how Sellers will receive equity in the combined group but does not state the aggregate purchase price, valuation, or expected financial effects. Investors should review the forthcoming proxy statement for those details, along with the directors' and executive officers' interests described in the solicitation disclosures.
02—Key points
Key Highlights
- Amendment No. 1 to the Membership Interests Purchase Agreement, dated April 11, 2025, adds Royalty Pharma plc as a party to the agreement with RPH, Royalty Pharma Manager, LLC and RP Management, LLC.
- At closing, Sellers will subscribe for Class B ordinary shares of Royalty Pharma plc equal in number to the non-voting Class E ordinary shares of RPH they receive as consideration.
- Class B shares will be issued to Sellers at nominal value of US$0.000001 per share, paid in cash at closing.
- The Transaction requires shareholder approval, and Royalty Pharma plc states it will file a Schedule 14A proxy statement seeking that approval.
- The filing does not state the aggregate consideration, valuation or expected financial impact of the Transaction.
- Pablo Legorreta is named as Seller Representative under the amended agreement.
03—Questions
Frequently Asked Questions
What is the Transaction Royalty Pharma is entering into?
RPH, a subsidiary of Royalty Pharma plc, agreed under a Membership Interests Purchase Agreement dated January 10, 2025 to acquire all equity interests of Royalty Pharma Manager, LLC (formerly Royalty Pharma, LLC) from the named Sellers, with RP Management, LLC also named in the agreement.
What does Amendment No. 1 change?
Amendment No. 1 makes Royalty Pharma plc a party to the Purchase Agreement so that Sellers can subscribe for Class B ordinary shares of the parent company equal in number to the non-voting Class E ordinary shares of RPH they receive as consideration, and so the company can issue those shares.
At what price will the Sellers subscribe for the Class B shares?
The Sellers will subscribe at the nominal value of US$0.000001 per share, with payment made in cash at closing of the Transaction.
What approvals are needed before the Transaction can close?
The filing states the Transaction is subject to shareholder approval. Royalty Pharma plc will file a proxy statement on Schedule 14A to seek that approval, and the filing directs investors to read it when available.
Does the filing disclose the financial terms of the Transaction?
No. The filing describes the equity structure and share subscription terms but does not state the aggregate consideration, valuation or expected financial effects of the Transaction.
04—Continue